{"product_id":"hca-vrio-analysis","title":"HCA Healthcare, Inc. (HCA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to HCA Healthcare, Inc. (HCA)'s market success! This VRIO analysis distills the company's core resources and capabilities down to their fundamental competitive potential - are they truly Valuable, Rare, Inimitable, and Organized for sustained advantage? Read on immediately to uncover the definitive answer that shapes HCA Healthcare, Inc. (HCA)'s future performance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eHCA Healthcare, Inc. (HCA) - VRIO Analysis: 1. Extensive Scale and Geographic Footprint\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at HCA Healthcare, Inc. (HCA) and wondering how their sheer size translates into a durable advantage. Honestly, it’s the bedrock of their entire operation. This massive footprint allows them to drive down costs and standardize care in ways smaller players simply cannot touch.\u003c\/p\u003e\n\u003cp\u003eThe value is clear in the numbers. As of the end of fiscal 2024, HCA operated \u003cstrong\u003e190 hospitals\u003c\/strong\u003e and roughly \u003cstrong\u003e2,400 ambulatory sites of care\u003c\/strong\u003e across 20 states and the United Kingdom. This scale is what helps them project revenues between \u003cstrong\u003e$72.80 billion and $75.80 billion\u003c\/strong\u003e for the 2025 fiscal year. Their operating margin for the trailing twelve months ending December 2025 was \u003cstrong\u003e12.07%\u003c\/strong\u003e, and their adjusted EBITDA margin topped \u003cstrong\u003e20% in 2025\u003c\/strong\u003e, showing the financial payoff from this density.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the VRIO assessment for this scale:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eJustification\/Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEnables economies of scale across \u003cstrong\u003e190 hospitals\u003c\/strong\u003e and \u003cstrong\u003e~2,400 sites of care\u003c\/strong\u003e, driving efficiency.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eLargest for-profit operator in the U.S.; few competitors match this density and geographic spread.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh Cost\/Time\u003c\/td\u003e\n\u003ctd\u003eReplicating the physical network and securing necessary regulatory approvals takes decades and massive capital outlay.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eLeverages centralized support functions, like supply-chain management, across the entire network of \u003cstrong\u003e~316,000 colleagues\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eScale is the foundation; it underpins cost leadership and makes catching up extremely difficult.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe rarity comes from being the biggest fish in the for-profit pond. Building that physical network - the hospitals, the surgery centers, the ERs - is incredibly hard to copy. It’s not just about money; it’s about time and navigating local regulations, like Certificate of Need laws, which can take years, if not decades. If onboarding new facilities takes 14+ days, churn risk rises, but HCA has already absorbed that initial pain point across their entire footprint.\u003c\/p\u003e\n\u003cp\u003eOrganizationally, HCA Healthcare is set up to extract every bit of efficiency from this size. They use centralized functions, think of it as a massive shared services center, for things like supply chain and data analytics. This structure is what turns physical scale into tangible financial results, like their projected \u003cstrong\u003e$14.30 to $15.10 billion\u003c\/strong\u003e in Adjusted EBITDA for 2025. This combination of physical presence and operational alignment creates a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. It’s defintely the core moat.\u003c\/p\u003e\n\u003cp\u003eRecommendations based on this analysis:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProtect supply chain contracts for cost leverage.\u003c\/li\u003e\n\u003cli\u003eInvest capital in high-density markets for further density.\u003c\/li\u003e\n\u003cli\u003eBenchmark outpatient margins against centralized standards.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eHCA Healthcare, Inc. (HCA) - VRIO Analysis: 2. Proprietary Physician and Nurse Pipeline\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly addresses the industry’s biggest constraint - labor - by owning educational assets like Galen College of Nursing and running teaching hospitals for GME programs.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGalen College of Nursing had 22 campuses in 2024.\u003c\/li\u003e\n\u003cli\u003eGalen College of Nursing had more than 17,600 students enrolled in 2024.\u003c\/li\u003e\n\u003cli\u003eHCA welcomed over 2,000 new residents and fellows to its GME programs on July 1, 2023.\u003c\/li\u003e\n\u003cli\u003eHCA is the largest sponsor of Graduate Medical Education (GME) programs in the United States.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate to High. Owning a major nursing college and running the largest GME sponsorship program is unique among for-profit peers.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGalen College of Nursing has opened 17 new campuses since joining HCA Healthcare in 2020.\u003c\/li\u003e\n\u003cli\u003eHCA Healthcare has 300+ residency and fellowship programs across 16 states.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Building a pipeline of over 44,000 affiliated physicians and a steady stream of new nurses is a long-term, capital-intensive process.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHCA had more than 45,000 active and affiliated physicians in its portfolio in 2023.\u003c\/li\u003e\n\u003cli\u003eHCA recruited 37,500 bedside nurses in 2023.\u003c\/li\u003e\n\u003cli\u003eHCA invested more than $200 million towards Galen College of Nursing's expansion since 2020.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. This pipeline directly feeds the operational needs of its facilities, linking education to employment strategy.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAffiliated Physicians\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e45,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eActive and affiliated physicians in portfolio\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistered Nurses\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e99,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2023\/2024\u003c\/td\u003e\n\u003ctd\u003eTotal registered nurses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalen College Campuses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eTotal campuses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew GME Residents\/Fellows Welcomed\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e2,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eJuly 1, 2023\u003c\/td\u003e\n\u003ctd\u003eIncoming class\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Labor as % of Total Labor Costs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003eProjected range for back half of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Labor as % of SWB Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2023\u003c\/td\u003e\n\u003ctd\u003eReported percentage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This internal talent sourcing lowers reliance on expensive contract labor over time.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHCA trimmed contract labor costs by 25.7% in Q2 2024 compared to Q2 2023.\u003c\/li\u003e\n\u003cli\u003eTotal labor costs in Q2 2024 were $\u003cstrong\u003e7.7 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIn 2024, HCA distributed $35 million to assist more than 11,500 colleagues pursue a nursing degree.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eHCA Healthcare, Inc. (HCA) - VRIO Analysis: 3. Data Analytics and AI Integration Engine\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Leverages data from \u003cstrong\u003e44 million\u003c\/strong\u003e annual patient encounters to create workflow efficiencies and clinical best practices. Clinical study identified a protocol that can reduce bloodstream infections in ICU patients by \u003cstrong\u003e44%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. HCA’s integration depth, leveraging data from \u003cstrong\u003e44 million\u003c\/strong\u003e encounters annually, is advanced for the sector.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. Proprietary data sets provide a head start over competitors rapidly adopting similar AI tools.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The dedicated Digital Transformation and Innovation (DT\u0026amp;I) department is focused on this value creation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Current lead is valuable for near-term margin improvement.\u003c\/p\u003e\n\u003cp\u003eThe scale of HCA’s data utilization and specific AI deployments are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eEngine Component\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eScale\/Deployment Figure\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eData Scale\u003c\/td\u003e\n\u003ctd\u003eAnnual Patient Encounters\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e44 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Scheduling (Timpani)\u003c\/td\u003e\n\u003ctd\u003eFacilities in Operation (as of initial rollout\/recent reports)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9\u003c\/strong\u003e facilities (initial launch)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Scheduling (Timpani)\u003c\/td\u003e\n\u003ctd\u003eColleagues Using Daily (as of a recent report)\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e7,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Documentation (Augmedix Go)\u003c\/td\u003e\n\u003ctd\u003ePhysicians in Pilot\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e80\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Documentation (Augmedix Go)\u003c\/td\u003e\n\u003ctd\u003eHospitals in Pilot\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific AI\/Digital Initiatives Include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTimpani: Automated scheduling and staffing platform, saving nursing leaders hundreds of hours.\u003c\/li\u003e\n\u003cli\u003eAugmedix Go: Ambient medical documentation tool in pilot with ER physicians.\u003c\/li\u003e\n\u003cli\u003eNurse Handoff: AI-driven solution in proof of concept testing at \u003cstrong\u003e4\u003c\/strong\u003e HCA Healthcare hospitals, with \u003cstrong\u003e89%\u003c\/strong\u003e of participating nurses rating it as helpful.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eHCA Healthcare, Inc. (HCA) - VRIO Analysis: 4. Superior Operational Efficiency and Margin Performance\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Consistently generates strong profitability. HCA Healthcare, Inc. reported an Operating Margin of \u003cstrong\u003e14.97%\u003c\/strong\u003e for the fiscal year ending 2024-12-31. The Return on Invested Capital (ROIC %) as of today (2025-11-29) based on TTM data is \u003cstrong\u003e18.68%\u003c\/strong\u003e. This ROIC is positioned above the market average ROIC of \u003cstrong\u003e11.3%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. HCA’s performance is notable when compared to key competitors:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTenet Healthcare (THC) Operating Margin: \u003cstrong\u003e25.39%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUniversal Health Services (UHS) Operating Margin: \u003cstrong\u003e9.46%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCommunity Health Systems (CYH) Operating Margin: \u003cstrong\u003e-2.23%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate. The scale advantage supports efficiency; as of 2024, HCA owned and operated \u003cstrong\u003e186 hospitals\u003c\/strong\u003e and employed roughly \u003cstrong\u003e309,000 employees\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High. Management has demonstrated discipline in margin expansion over time. The NOPAT margin improved from \u003cstrong\u003e11.6% in 2019\u003c\/strong\u003e to \u003cstrong\u003e12.5% in the TTM\u003c\/strong\u003e ended 3Q25, driving ROIC from \u003cstrong\u003e16% in 2019\u003c\/strong\u003e to \u003cstrong\u003e19% in the TTM\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained. Operational efficiency is supported by scale and historical margin improvement trends.\u003c\/p\u003e\n\u003cp\u003eKey Financial and Operational Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14.97%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended 2024-12-31\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eROIC % (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.68%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of 2025-11-29\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eROIC % (Annual)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.28%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Average ROIC %\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarket Average\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (FY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$64.968 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA (FY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.726 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNOPAT Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTTM ended 3Q25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOperational Scale and Growth Indicators:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEquivalent admissions rose \u003cstrong\u003e3% compounded annually\u003c\/strong\u003e from 3.0 million in 2014 to \u003cstrong\u003e4.1 million\u003c\/strong\u003e in the TTM ended 3Q25.\u003c\/li\u003e\n\u003cli\u003eRevenue compounded annually by \u003cstrong\u003e6%\u003c\/strong\u003e since 2007.\u003c\/li\u003e\n\u003cli\u003eNet Operating Profit After Tax (NOPAT) compounded annually by \u003cstrong\u003e7%\u003c\/strong\u003e since 2007.\u003c\/li\u003e\n\u003cli\u003eHCA operated \u003cstrong\u003e180 general, acute care hospitals\u003c\/strong\u003e out of 190 total facilities at the end of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eHCA Healthcare, Inc. (HCA) - VRIO Analysis: 5. Payer Contracting Leverage\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 id=\"value\"\u003eValue\u003c\/h3\u003e\n\u003cp\u003eMassive scale supports bargaining power, evidenced by 2024 total revenues of $70.603 billion and 2025 projected revenues between $72.80 billion and $75.80 billion. This scale drives favorable terms.\u003c\/p\u003e\n\n\u003ch3 id=\"rarity\"\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eSecuring favorable terms early is rare, with HCA finalizing more than 90% of 2025 contracts and approximately 75% of 2026 contracts at mid-single digit escalators. Historical commercial escalation was around 3.5-4%, with current negotiations achieving a 100 bps premium on the low side.\u003c\/p\u003e\n\n\u003ch3 id=\"imitability\"\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors lack the necessary volume leverage, which is reflected in HCA's operational scale metrics compared to historical data points:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eHCA Scale Data Point\u003c\/th\u003e\n\u003cth\u003eContext Year\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals Operated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e190\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquivalent Admissions (Millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTTM ended 3Q25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected 2025 Adjusted EBITDA (Billions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.30 to $15.10\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025 Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3 id=\"organization\"\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eCentralized management maximizes enterprise-wide rate escalators, contributing to margin expansion:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdjusted EBITDA margin expanded from 19.3% (prior year) to 20.4% in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eSalaries and Benefits (SWB) as a percentage of net revenue was 43.6% in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eContract labor reduced to 4.6% of total labor costs, down 18% from the prior year.\u003c\/li\u003e\n\u003cli\u003eAnticipated 2.5-3.5% wage increases for 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3 id=\"competitiveadvantage\"\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e. Leverage is directly tied to irreplaceable scale, supporting 2025 EPS guidance of $24.05 to $25.85 per diluted share.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eHCA Healthcare, Inc. (HCA) - VRIO Analysis: 6. Disciplined Capital Deployment\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eManagement balances significant reinvestment with returning capital to shareholders.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProjected Capital Expenditures (CapEx) for 2025, excluding acquisitions, range from \u003cstrong\u003e$5.0 billion\u003c\/strong\u003e to \u003cstrong\u003e$5.2 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eManagement has deployed over \u003cstrong\u003e$10 billion\u003c\/strong\u003e into share repurchases since 2023.\u003c\/li\u003e\n\u003cli\u003eShare repurchases in the third quarter of 2025 totaled \u003cstrong\u003e$2.498 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShare repurchases in the first nine months of 2025 totaled approximately \u003cstrong\u003e$7.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. HCA’s ability to generate high Free Cash Flow yield supports this dual strategy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHCA’s Free Cash Flow (FCF) yield was reported at \u003cstrong\u003e8.51%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Trailing Twelve Month (TTM) FCF Yield as of November 17, 2025, was \u003cstrong\u003e7.44%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe market average FCF yield is \u003cstrong\u003e2.01%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. Competitors can execute buybacks, but only if they generate comparable cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. The discipline shown in capital allocation supports its high Return on Invested Capital (ROIC).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eHCA Figure\u003c\/td\u003e\n\u003ctd\u003eContext\/Period\u003c\/td\u003e\n\u003ctd\u003eMarket\/Peer Average\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected 2025 CapEx (Excl. Acq.)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.0 billion\u003c\/strong\u003e to \u003cstrong\u003e$5.2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2025 Guidance\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported ROIC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnualized ROIC\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.73%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter ended September 2025\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM FCF Yield\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.44%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 17, 2025\u003c\/td\u003e\n\u003ctd\u003eIndustry Median: \u003cstrong\u003e1.385%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. While strong now, market conditions could pressure this balance in the future.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eHCA Healthcare, Inc. (HCA) - VRIO Analysis: 7. Clinical Quality Benchmarking and Reputation\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA large portion of its facilities meet top-tier quality standards, with \u003cstrong\u003e49\u003c\/strong\u003e hospitals recognized on the 2025 Healthgrades America's 250 Best Hospitals list, representing the top \u003cstrong\u003e5%\u003c\/strong\u003e of hospitals in the country for clinical excellence.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. While quality is universal, achieving top-tier recognition across nearly \u003cstrong\u003e50\u003c\/strong\u003e facilities is a significant achievement. The sustained recognition across multiple facilities is less common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. Quality standards can be adopted, but sustained excellence requires deep cultural commitment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. Quality improvement is a daily discipline supported by enterprise-wide data analysis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. Quality is a baseline expectation, but their proven track record is a differentiator.\u003c\/p\u003e\n\u003cp\u003eKey Clinical Quality Benchmarks and Recognition:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\/Award\u003c\/th\u003e\n\u003cth\u003eCount\/Level\u003c\/th\u003e\n\u003cth\u003eYear\/Period\u003c\/th\u003e\n\u003cth\u003eSignificance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthgrades America's 250 Best Hospitals\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e49\u003c\/strong\u003e Hospitals\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eTop \u003cstrong\u003e5%\u003c\/strong\u003e of hospitals nationwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthgrades America's 100 Best Hospitals\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e Hospitals\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eTop \u003cstrong\u003e2%\u003c\/strong\u003e of hospitals nationwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthgrades America's 50 Best Hospitals\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e Hospital (Mission Hospital)\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003eTop \u003cstrong\u003e1%\u003c\/strong\u003e in the nation for consistent clinical excellence (\u003cstrong\u003e10th\u003c\/strong\u003e consecutive year)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthgrades Patient Safety Excellence Awards\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e100\u003c\/strong\u003e Hospitals recognized in top \u003cstrong\u003e10%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2024 Awards (recognized in 2025)\u003c\/td\u003e\n\u003ctd\u003eTop decile for patient safety\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS 5-Star Hospitals Rating\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13\u003c\/strong\u003e Hospitals\u003c\/td\u003e\n\u003ctd\u003eJuly 2024 Release\u003c\/td\u003e\n\u003ctd\u003eHighest level performance across multiple domains\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eEnterprise-level data utilization supporting quality:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnalysis of more than \u003cstrong\u003e9 million\u003c\/strong\u003e emergency room patient encounters annually to develop best practices.\u003c\/li\u003e\n\u003cli\u003eA clinical protocol identified via internal study reduced bloodstream infections in ICU patients by \u003cstrong\u003e44%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e32\u003c\/strong\u003e HCA Healthcare hospitals recognized on the Fortune\/PINC AI 100 Top Hospitals list for 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eHCA Healthcare, Inc. (HCA) - VRIO Analysis: 8. Diversified, Integrated Site-of-Care Network\n\u003c\/h2\u003e\n\u003cp\u003eValue: The network spans the full continuum - hospitals, freestanding surgery centers, emergency rooms, and clinics, allowing HCA to capture patient volume across acuity levels and optimize site selection.\u003c\/p\u003e\n\u003cp\u003eAs of December 31, 2024, HCA operated 190 hospitals and approximately 2,400 ambulatory sites of care across 20 states and the United Kingdom.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSite of Care Category\u003c\/th\u003e\n\u003cth\u003eCount (As of Dec 31, 2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e190\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmbulatory Sites of Care (Total)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e2,400\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgery Centers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e124\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreestanding Emergency Rooms\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e173\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrgent Care Clinics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e341\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician Clinics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,622\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eRarity: Moderate. While many systems have multiple sites, HCA’s integrated, multi-state footprint is vast and strategically placed.\u003c\/p\u003e\n\u003cp\u003eHCA has the most hospitals in Texas with 76, followed by Florida with 51.\u003c\/p\u003e\n\u003cp\u003eImitability: High. Building out this density of access points across 20 states is a massive undertaking.\u003c\/p\u003e\n\u003cp\u003eApproximately $6 billion of projects were under development as of the end of 2024, slated to come online over the next few years.\u003c\/p\u003e\n\u003cp\u003eOrganization: High. This structure supports the strategy of adding more sites of care per hospital to drive volume growth.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSame facility inpatient admissions increased 4.5% Year-over-Year (YoY) in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eSame facility Emergency Room (ER) Visits rose 4.6% YoY in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eSame facility equivalent admissions increased 3.1% YoY in the fourth quarter of 2024 compared to the prior year period.\u003c\/li\u003e\n\u003cli\u003eOutpatient Surgery cases declined 1.3% YoY in Q4 2024.\u003c\/li\u003e\n\u003cli\u003eRevenues for the year ended December 31, 2024, totaled $70.603 billion.\u003c\/li\u003e\n\u003cli\u003eNet income attributable to HCA Healthcare, Inc. for the year ended December 31, 2024, was $5.760 billion.\u003c\/li\u003e\n\u003cli\u003eHCA incurred $7.2 billion in federal, state and local taxes in 2024.\u003c\/li\u003e\n\u003cli\u003eEstimated cost for charity care, uninsured discounts, and other uncompensated care in 2024 was approximately $4.4 billion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCompetitive Advantage: Sustained. The integrated network makes it difficult for specialized competitors to poach volume across the care spectrum.\u003c\/p\u003e\n\u003cp\u003eSame-facility revenue grew by 7.1% Year-over-Year in the third quarter of 2024.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eHCA Healthcare, Inc. (HCA) - VRIO Analysis: 9. Enterprise-Level Resilience and Disaster Response\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eEnterprise-Level Resilience and Disaster Response\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Its sheer size and standardized processes allow it to be resilient in the face of challenges or disasters, learning and innovating at scale across the system. The system operated \u003cstrong\u003e190 hospitals\u003c\/strong\u003e and approximately \u003cstrong\u003e2,400 ambulatory sites of care\u003c\/strong\u003e across 20 states and the United Kingdom as of December 31, 2024. The system reported revenues of \u003cstrong\u003e$70.603 billion\u003c\/strong\u003e for the year ended December 31, 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Few private systems have the operational depth to manage large-scale emergencies consistently across multiple regions. The system is ranked #\u003cstrong\u003e61\u003c\/strong\u003e on the Fortune 500 rankings of the largest United States corporations by total revenue as of 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. This resilience is an emergent property of its scale, data infrastructure, and standardized protocols. The company incurred estimated losses of \u003cstrong\u003e$250 million\u003c\/strong\u003e associated with Hurricanes Helene and Milton on its North Carolina and Florida facilities in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The ability to deploy resources and learn from events quickly across the network is a key organizational strength. The company is utilizing advanced AI and predictive analytics in real-time perinatal care through the CareIntellect for Perinatal platform, announced in October 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This capability is a direct, non-replicable outcome of its size and operational maturity.\u003c\/p\u003e\n\u003cp\u003eThe projected \u003cstrong\u003e$5.0 billion\u003c\/strong\u003e to \u003cstrong\u003e$5.2 billion\u003c\/strong\u003e Capital Expenditures for 2025, excluding acquisitions, demonstrates commitment to system maintenance and enhancement.\u003c\/p\u003e\n\u003cp\u003eThe following table illustrates the scale of recent financial performance and planned investment, relevant to enterprise resilience:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003ePeriod\/Projection\u003c\/th\u003e\n\u003cth\u003eAmount (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected 2025 Capital Expenditures (Excluding Acquisitions)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Estimate\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.0 billion\u003c\/strong\u003e to \u003cstrong\u003e$5.2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flows Provided by Operating Activities\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.416 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flows Provided by Operating Activities\u003c\/td\u003e\n\u003ctd\u003eQ4 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.559 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$997 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$44.511 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected 2025 Revenues (Latest Guidance)\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025 Estimate\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$75 billion\u003c\/strong\u003e to \u003cstrong\u003e$76.5 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational capacity to absorb significant, localized financial shocks, such as the estimated \u003cstrong\u003e$250 million\u003c\/strong\u003e impact from two major hurricanes in 2024, is supported by its overall financial scale and operational continuity protocols.\u003c\/p\u003e\n\u003cp\u003eKey operational and financial indicators supporting resilience:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEquivalent admissions growth projected between \u003cstrong\u003e2%\u003c\/strong\u003e and \u003cstrong\u003e3%\u003c\/strong\u003e for the full year 2025.\u003c\/li\u003e\n\u003cli\u003eLatest full-year 2025 Net Income guidance range: \u003cstrong\u003e$6.495 billion\u003c\/strong\u003e to \u003cstrong\u003e$6.715 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLatest full-year 2025 Adjusted EBITDA guidance range: \u003cstrong\u003e$15.250 billion\u003c\/strong\u003e to \u003cstrong\u003e$15.650 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the nine months ended September 30, 2025, Net Income Attributable to HCA Healthcare, Inc. was \u003cstrong\u003e$4.906 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516176654485,"sku":"hca-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/hca-vrio-analysis.png?v=1740180748","url":"https:\/\/dcf-model.com\/pt\/products\/hca-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}